Advocates on Steps of Congress 2013
Please leave this field empty
Scleroderma Foundation
Homepage | Forward to a Friend | Make a Donation
eletter banner.jpg
eLetter #724 | August 18, 2017  

CaregiverCaring For Caregivers

How to address the stress of taking care of older relatives and friends

By Ron Adelman, M.D.

Published July 28, 2017 at 10:53 am (updated July 28, 2017)

Read more

Patient Voices: Sjögren's Syndrome

By Karen Barrow

New York Times Logo

This interactive section of The New York Times website shares stories of patients with Sjögren Syndrome. Over 20 percent of patients with systemic sclerosis and a few with localized scleroderma also have Sjögren Syndrome. It is more often detected in persons with the limited form of systemic sclerosis. The symptoms and examination findings and methods of diagnosis and treatment in Sjögren Syndrome in scleroderma patients are identical to those in primary Sjögren Syndrome.

Read more

Scleroderma and Your Gut Feelings: Managing GI Involvement

Webinar, Wednesday, August 23, 2017; 7 p.m. - 8 p.m. Eastern

Michigan Webinar Aug. 2017
Join us for a free webinar in the comfort of your own home hosted by Dr. Dinesh Khanna from the University of Michigan on Managing GI Involvement. There is no sign-up necessary. Join the meeting here just prior to the start time.

Discovery Documentary: First in Human

Final episode Thursday evening August 24 at 9:00 p.m. ET/PT on Discovery.

Discovery Documentary
First in Human
is a three-part documentary capturing the real-life experiences of doctors, researchers, staff, patients and their caregivers, at the NIH Clinical Center.* The documentary airs on three sequential Thursday evenings on August 10, 17, and 24, at 9:00 p.m. ET/PT on Discovery.

Read more

Clinical Trial News

Genentech Completes Phase III Enrollment for Study of Actemra in Systemic Sclerosis

Genentech has completed enrollment for a Phase III clinical trial investigating the use of Actemra (tocilizumab) in patients with systemic sclerosis (also known as scleroderma). Overall, 211 patients were enrolled just over 15 months in 106 activated sites around the world.

Genentech announced that the FDA granted Breakthrough Therapy Designation to Actemra for the treatment of systemic sclerosis at EULAR 2015, during which Phase II data were presented and the initiation of the Phase III clinical trial was also announced. Follow the link below to read the original press release regarding the Breakthrough Therapy Designation.

Read more

Quick Links
Advocacy
Contact Us
Become a Member
About Scleroderma
Calendar of Events
Online Chat
Store
Make a gift
Home
facebook_32.png
twitter_32.png
2016 Instagram
Youtube_32x32.png
 actelion new.jpg
Bayer logo
Gilead Logo
reata small
Genentech Logo
Boehringer Ingelheim
 
 

 

Disclaimer: The Scleroderma Foundation in no way endorses any drugs, treatments, clinical trials, or studies reported in the eLetter. Information is provided to keep the readers informed. Because the manifestations and severity of scleroderma vary among individuals, personalized medical management is essential. Therefore, it is strongly recommended that all drugs and treatments be discussed with the reader’s physician(s) for proper evaluation and treatment.

Powered by Blackbaud  Unsubscribe | Visit our web site | Contact Us | Donate
300 Rosewood Drive, Suite 105, Danvers, MA 01923 tel: 800-722-HOPE (4673)
© 2017 All rights reserved.